Understanding why women reject personalized breast cancer risk information
Understanding and Addressing Rejection of Personalized Cancer Risk Information
This study is trying to understand why some women choose not to accept personalized breast cancer risk information and how that affects their decisions about getting mammograms.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 750 (estimated) |
| Ages | 39 Years to 74 Years |
| Sex | Female |
| Sponsor | University of Colorado, Denver Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Aurora, Colorado and 1 other locations) |
| Trial ID | NCT06441474 on ClinicalTrials.gov |
What this trial studies
This study investigates the reasons behind women's rejection of personalized breast cancer risk information in relation to mammography screening. It aims to identify demographic and psychological factors that contribute to this rejection and how it affects screening behaviors. Participants will receive a personalized breast cancer risk estimate using the Breast Cancer Risk Assessment Tool (BCRAT) and will complete surveys at baseline and after 12 months to assess their responses and screening decisions.
Who should consider this trial
Good fit: Ideal candidates are women aged 39-74 who are eligible for routine breast cancer screening and can understand English.
Not a fit: Patients with a prior diagnosis of breast cancer or certain genetic predispositions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve breast cancer screening rates by addressing the factors that lead to risk information rejection.
How similar studies have performed: Other studies have explored risk communication in cancer screening, but this specific focus on risk rejection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Female sex 2. Age 39-74 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision) 3. English literacy Exclusion Criteria: 1. Prior diagnosis of 1. breast cancer 2. Ductal carcinoma in situ (DCIS) 3. Lobular carcinoma in situ (LCIS) 4. Known BRCA1/2 gene mutation 5. Cowan syndrome 6. Li-Fraumeni syndrome 7. Having received previous chest radiation for treatment of Hodgkin's lymphoma.
Where this trial is running
Aurora, Colorado and 1 other locations
- University of Colorado Denver — Aurora, Colorado, United States (Recruiting)
- Washington University in St. Louis — Saint Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Laura Scherer, PhD — University of Colorado, Denver
- Study coordinator: Damilola Jolaoso, MSc
- Email: Damilola.Jolaoso@cuanschutz.edu
- Phone: 303-724-2504
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.